Clinical Trial Update: Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Vedolizumab as first-line therapy for immune checkpoint inhibitor–related colitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Checkpoint Inhibitor-related Colitis

Drugs mentioned

• Entyvio (vedolizumab)

Snippet

Sponsor: Shilpa Grover, MD, MPH | Conditions: Immune Checkpoint Inhibitor-Related Colitis | Phase 2 | Status: RECRUITING